Alnylam Pharmaceuticals, Inc. provided earnings guidance for full year ending December 31, 2024. For the year, the company expected combined net product revenues of $1,400 million to $1,500 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
153.3 USD | +0.36% | +2.06% | -19.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.78% | 19.33B | |
+49.15% | 57.87B | |
+41.65% | 40.25B | |
-6.90% | 39.94B | |
-5.96% | 28.54B | |
+13.04% | 26.4B | |
+31.75% | 12.4B | |
+0.19% | 12.23B | |
+25.52% | 12.2B | |
-9.14% | 11.06B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024